About the Multiple Myeloma Research Foundation

kathi-giusti-72dpiThe MMRF relentlessly pursues innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. After being diagnosed with multiple myeloma in 1998, Kathy Giusti and her sister Karen Andrews, a successful corporate attorney, founded the MMRF with the hope of one day finding a cure for this fatal blood cancer. Leveraging her past experience as a graduate of Harvard Business School and leader of a major pharmaceutical company, Kathy applied her business savvy to the science of cancer research. She and the MMRF identified barriers slowing drug development, particularly in an uncommon heterogeneous disease like multiple myeloma, and developed collaborative models to overcome those obstacles.

Optimized to run like a Fortune 500 company, with a culture of speed, innovation, and results—the MMRF remains laser focused on accelerating new and better treatments for patients, leading toward a cure.

The success of the MMRF is a reflection of the researchers, clinicians and industry partners who have helped build game-changing models in tissue banking, genomics, clinical trials, and open access—leading not only to transforming myeloma research but becoming the blueprint for other cancer organizations around the world.

As an end-to-end solution to accelerate drug development, the MMRF is dedicated to making sure the next generation of treatments is brought to patients as quickly as possible – from bridging drug discovery gaps through our innovative research portfolio and funding early-stage research, to developing novel business solutions that inject speed and efficiency into every step along the drug development pathway.